Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis

W. B. Gerecht, N. K. Henry, W. W. Hoffman, S. M. Muller, Nicholas F La Russo, J. E. Rosenblatt, W. R. Wilson

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Forty-six patients with cholangitis were randomized to receive therapy with mezlocillin sodium (24 patients) or a combination of ampicillin sodium-gentamicin sulfate (22 patients). The biliary concentration of mezlocillin was 112 times higher than that of ampicillin and 778 times higher than that of gentamicin. The ratio of the concentration in serum or bile over the minimum inhibitory concentration against aerobic gram-negative bacilli (therapeutic index) was higher for mezlocillin than for either ampicillin or gentamicin. Twenty (83%) of 24 patients were cured following mezlocillin therapy compared with 9 (41%) of 22 patients after ampicillin-gentamicin therapy. The 3 patients with superinfection were in the ampicillin-gentamicin arm of the study. Fewer toxic or adverse effects occurred in association with mezlocillin treatment than with ampicillin-gentamicin treatment. Mezlocillin therapy was more effective, less toxic, and less expensive than treatment with ampicillin and gentamicin for patients with cholangitis.

Original languageEnglish (US)
Pages (from-to)1279-1284
Number of pages6
JournalArchives of Internal Medicine
Volume149
Issue number6
StatePublished - 1989

Fingerprint

Mezlocillin
Cholangitis
Ampicillin
Gentamicins
Poisons
Therapeutics
Superinfection
Microbial Sensitivity Tests
Bile
Bacillus

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Gerecht, W. B., Henry, N. K., Hoffman, W. W., Muller, S. M., La Russo, N. F., Rosenblatt, J. E., & Wilson, W. R. (1989). Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Archives of Internal Medicine, 149(6), 1279-1284.

Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. / Gerecht, W. B.; Henry, N. K.; Hoffman, W. W.; Muller, S. M.; La Russo, Nicholas F; Rosenblatt, J. E.; Wilson, W. R.

In: Archives of Internal Medicine, Vol. 149, No. 6, 1989, p. 1279-1284.

Research output: Contribution to journalArticle

Gerecht, W. B. ; Henry, N. K. ; Hoffman, W. W. ; Muller, S. M. ; La Russo, Nicholas F ; Rosenblatt, J. E. ; Wilson, W. R. / Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. In: Archives of Internal Medicine. 1989 ; Vol. 149, No. 6. pp. 1279-1284.
@article{d5393bc162734ca48e369b030d4ccbae,
title = "Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis",
abstract = "Forty-six patients with cholangitis were randomized to receive therapy with mezlocillin sodium (24 patients) or a combination of ampicillin sodium-gentamicin sulfate (22 patients). The biliary concentration of mezlocillin was 112 times higher than that of ampicillin and 778 times higher than that of gentamicin. The ratio of the concentration in serum or bile over the minimum inhibitory concentration against aerobic gram-negative bacilli (therapeutic index) was higher for mezlocillin than for either ampicillin or gentamicin. Twenty (83{\%}) of 24 patients were cured following mezlocillin therapy compared with 9 (41{\%}) of 22 patients after ampicillin-gentamicin therapy. The 3 patients with superinfection were in the ampicillin-gentamicin arm of the study. Fewer toxic or adverse effects occurred in association with mezlocillin treatment than with ampicillin-gentamicin treatment. Mezlocillin therapy was more effective, less toxic, and less expensive than treatment with ampicillin and gentamicin for patients with cholangitis.",
author = "Gerecht, {W. B.} and Henry, {N. K.} and Hoffman, {W. W.} and Muller, {S. M.} and {La Russo}, {Nicholas F} and Rosenblatt, {J. E.} and Wilson, {W. R.}",
year = "1989",
language = "English (US)",
volume = "149",
pages = "1279--1284",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis

AU - Gerecht, W. B.

AU - Henry, N. K.

AU - Hoffman, W. W.

AU - Muller, S. M.

AU - La Russo, Nicholas F

AU - Rosenblatt, J. E.

AU - Wilson, W. R.

PY - 1989

Y1 - 1989

N2 - Forty-six patients with cholangitis were randomized to receive therapy with mezlocillin sodium (24 patients) or a combination of ampicillin sodium-gentamicin sulfate (22 patients). The biliary concentration of mezlocillin was 112 times higher than that of ampicillin and 778 times higher than that of gentamicin. The ratio of the concentration in serum or bile over the minimum inhibitory concentration against aerobic gram-negative bacilli (therapeutic index) was higher for mezlocillin than for either ampicillin or gentamicin. Twenty (83%) of 24 patients were cured following mezlocillin therapy compared with 9 (41%) of 22 patients after ampicillin-gentamicin therapy. The 3 patients with superinfection were in the ampicillin-gentamicin arm of the study. Fewer toxic or adverse effects occurred in association with mezlocillin treatment than with ampicillin-gentamicin treatment. Mezlocillin therapy was more effective, less toxic, and less expensive than treatment with ampicillin and gentamicin for patients with cholangitis.

AB - Forty-six patients with cholangitis were randomized to receive therapy with mezlocillin sodium (24 patients) or a combination of ampicillin sodium-gentamicin sulfate (22 patients). The biliary concentration of mezlocillin was 112 times higher than that of ampicillin and 778 times higher than that of gentamicin. The ratio of the concentration in serum or bile over the minimum inhibitory concentration against aerobic gram-negative bacilli (therapeutic index) was higher for mezlocillin than for either ampicillin or gentamicin. Twenty (83%) of 24 patients were cured following mezlocillin therapy compared with 9 (41%) of 22 patients after ampicillin-gentamicin therapy. The 3 patients with superinfection were in the ampicillin-gentamicin arm of the study. Fewer toxic or adverse effects occurred in association with mezlocillin treatment than with ampicillin-gentamicin treatment. Mezlocillin therapy was more effective, less toxic, and less expensive than treatment with ampicillin and gentamicin for patients with cholangitis.

UR - http://www.scopus.com/inward/record.url?scp=0024329912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024329912&partnerID=8YFLogxK

M3 - Article

C2 - 2658897

AN - SCOPUS:0024329912

VL - 149

SP - 1279

EP - 1284

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 6

ER -